|Mr. Sean Carrick||Pres, CEO, Sec. & Director||252k||N/A||1968|
|Mr. Lowell Holden||CFO, Chief Accounting Officer & Director||180k||N/A||1943|
|Dr. Mark C. Glassy||Founder & Chairman of Scientific Advisory Board||N/A||N/A||1952|
|Dr. Navpaul Singh M.D.||Chief Medical Consultant||N/A||N/A||N/A|
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
Nascent Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.